Literature DB >> 1529984

Evaluation of six computerized drug interaction screening programs.

C A Jankel1, B C Martin.   

Abstract

Six widely used computerized drug interaction screening programs were evaluated according to criteria developed by a panel of pharmacists. A panel of six pharmacists from various practice settings developed criteria that were used to evaluate six computerized drug interaction screening programs: Medicom Micro Plus, Medical Letter, S-O-A-P, Drug Interactions by Hansten, Drug Therapy Screening Systems (DTSS), and RxTriage. The criteria were that the programs be user friendly and efficient, provide guidance, and be relevant to the user's practice setting. Also, they should detect interactions, quickly alert the user, and guide the user to the appropriate action. The user should be able to set the level of clinical significance, screen only current drugs in a patient profile, and print out summaries. The panel selected nine known drug interactions to test the programs' knowledge bases. Only Medicom Micro Plus and DTSS detected all nine drug interactions; Medical Letter missed three. RxTriage and Drug Interactions received the highest ratings in user friendliness and efficiency, but both missed two interactions. RxTriage was rated most relevant to their practice by hospital and community pharmacists, and Drug Interactions was rated most relevant by faculty practitioners. S-O-A-P received low ratings overall. Of the six drug interaction screening programs evaluated, none was considered by the panel of pharmacists to be ideal.

Entities:  

Mesh:

Year:  1992        PMID: 1529984

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  8 in total

1.  Evaluation of frequently used drug interaction screening programs.

Authors:  Priska Vonbach; André Dubied; Stephan Krähenbühl; Jürg H Beer
Journal:  Pharm World Sci       Date:  2008-04-16

2.  Medication control in hospitals: a practical approach to the problem of drug-drug interactions.

Authors:  E H Wiltink
Journal:  Pharm World Sci       Date:  1998-08

3.  Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant.

Authors:  Bente Glintborg; Stig Ejdrup Andersen; Kim Dalhoff
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

4.  Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients.

Authors:  Olesya I Zorina; Patrick Haueis; Waldemar Greil; Renate Grohmann; Gerd A Kullak-Ublick; Stefan Russmann
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

5.  Identification of adverse drug reactions in geriatric inpatients using a computerised drug database.

Authors:  Tobias Egger; Harald Dormann; Gabi Ahne; Ulrich Runge; Antje Neubert; Manfred Criegee-Rieck; Karl G Gassmann; Kay Brune
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Recommendations for selecting drug-drug interactions for clinical decision support.

Authors:  Hugh Tilson; Lisa E Hines; Gerald McEvoy; David M Weinstein; Philip D Hansten; Karl Matuszewski; Marianne le Comte; Stefanie Higby-Baker; Joseph T Hanlon; Lynn Pezzullo; Kathleen Vieson; Amy L Helwig; Shiew-Mei Huang; Anthony Perre; David W Bates; John Poikonen; Michael A Wittie; Amy J Grizzle; Mary Brown; Daniel C Malone
Journal:  Am J Health Syst Pharm       Date:  2016-04-15       Impact factor: 2.637

Review 7.  The evidence for the effectiveness of safety alerts in electronic patient medication record systems at the point of pharmacy order entry: a systematic review.

Authors:  Oluwagbemileke Ojeleye; Anthony Avery; Vaibhav Gupta; Matthew Boyd
Journal:  BMC Med Inform Decis Mak       Date:  2013-07-01       Impact factor: 2.796

8.  Assessing the safety features of electronic patient medication record systems used in community pharmacies in England.

Authors:  Oluwagbemileke Ojeleye; Anthony J Avery; Matthew J Boyd
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.